CL2019003708A1 - Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas. - Google Patents

Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas.

Info

Publication number
CL2019003708A1
CL2019003708A1 CL2019003708A CL2019003708A CL2019003708A1 CL 2019003708 A1 CL2019003708 A1 CL 2019003708A1 CL 2019003708 A CL2019003708 A CL 2019003708A CL 2019003708 A CL2019003708 A CL 2019003708A CL 2019003708 A1 CL2019003708 A1 CL 2019003708A1
Authority
CL
Chile
Prior art keywords
mitoketoskines
mitochondria
cancer cells
therapeutic agents
compounds
Prior art date
Application number
CL2019003708A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CL2019003708A1 publication Critical patent/CL2019003708A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A COMPUESTOS QUE SE ENLAZAN A POR LO MENOS UNA DE ACAT1/2 Y OXCT1/2 E INHIBEN LA PRODUCCIÓN MITOCONDRIAL DE ATP, REFERIDOS EN ESTE DOCUMENTO COMO MITOCETOSCINAS. SE DAN A CONOCER MÉTODOS DE PROSPECCIÓN DE COMPUESTOS POR LA INHIBICIÓN MITOCONDRIAL Y PROPIEDADES ANTICANCEROSAS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR MITOCETOSCINAS PARA PREVENIR O TRATAR CÁNCER, INFECCIONES BACTERIANAS Y LEVADURA PATÓGENA, ASÍ COMO TAMBIÉN MÉTODOS PARA USAR MITOCETOSCINAS PARA PROPORCIONAR BENEFICIOS ANTIENVEJECIMIENTO. TAMBIÉN SE DAN A CONOCER COMPUESTOS DE MITOCETOSCINA ESPECÍFICOS.
CL2019003708A 2017-06-26 2019-12-17 Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas. CL2019003708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762524829P 2017-06-26 2017-06-26

Publications (1)

Publication Number Publication Date
CL2019003708A1 true CL2019003708A1 (es) 2020-05-15

Family

ID=64742979

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003708A CL2019003708A1 (es) 2017-06-26 2019-12-17 Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas.

Country Status (21)

Country Link
US (2) US11667639B2 (es)
EP (1) EP3644988B1 (es)
JP (1) JP7397672B2 (es)
KR (2) KR102646172B1 (es)
CN (1) CN110913854B (es)
AU (2) AU2018292283B2 (es)
CA (1) CA3064452A1 (es)
CL (1) CL2019003708A1 (es)
CO (1) CO2019014259A2 (es)
CR (1) CR20200033A (es)
CU (1) CU20190106A7 (es)
DO (2) DOP2019000312A (es)
EC (1) ECSP20001729A (es)
IL (2) IL292109B2 (es)
MX (1) MX2019014806A (es)
PE (2) PE20200295A1 (es)
PH (1) PH12019502892A1 (es)
RU (1) RU2020102908A (es)
SG (1) SG11201913134UA (es)
WO (1) WO2019005698A1 (es)
ZA (2) ZA201907831B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064452A1 (en) * 2017-06-26 2019-01-03 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
CA3078791A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. Anti-mitochondrial inhibitors for oncogenic ras and myc
SG11202003739SA (en) * 2017-11-03 2020-05-28 Bioimics Ab Anti-infective heterocyclic compounds and uses thereof
WO2019232161A1 (en) 2018-06-01 2019-12-05 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
PE20211006A1 (es) 2018-10-02 2021-06-01 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como farmacos senoliticos
EP3976197B1 (en) 2019-05-24 2025-07-16 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
EP0310361A3 (en) 1987-09-30 1989-05-24 Beckman Instruments, Inc. Tridentate conjugate and method of use thereof
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
EP0656422B1 (en) 1993-11-05 2000-04-26 Amersham Pharmacia Biotech UK Limited Chloramphenicol acetyl transferase (CAT) assay
WO1995015770A1 (en) 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
CA2219277A1 (en) 1995-05-03 1996-11-07 Pfizer Limited Novel tetracycline derivatives
JP4590523B2 (ja) 1997-11-25 2010-12-01 アンティポディーン ファーマシューティカルズ インコーポレイテッド ミトコンドリアを標的とする抗酸化剤
DK0941998T3 (da) 1998-03-03 2004-09-20 Pfizer Prod Inc 3,6-ketalmakrolidantibiotika
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
EP2517729A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
TWI324600B (en) 2003-07-07 2010-05-11 Kowa Co 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound
WO2005062851A2 (en) 2003-12-22 2005-07-14 Pappolla Miguel A Indole-3-propionamide and derivatives thereof
CA2557215A1 (en) 2004-02-26 2005-09-09 Advanced Ocular Systems Limited Tetracycline derivatives for the treatment of ocular pathologies
US20060083727A1 (en) 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ATE523519T1 (de) 2005-01-14 2011-09-15 Glaxo Group Ltd Makrolidverbindungen mit biotin und fotoaffinitätsgruppe zur identifizierung eines makrolid-targets
CN101242822B (zh) 2005-07-18 2011-08-24 彼帕科学公司 治疗卵巢癌的药物
MX2008014953A (es) 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
JP2009539769A (ja) 2006-06-02 2009-11-19 アリアド ジーン セラピューティクス インコーポレイテッド カペシタビン併用療法
US20070292906A1 (en) 2006-06-14 2007-12-20 Bristol-Myers Squibb Company Assay for measuring acyltransferase activity
MX2009004748A (es) 2006-10-30 2009-08-25 Southern Res Inst Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
US8075902B2 (en) 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
US8647673B2 (en) 2007-07-24 2014-02-11 Wayne State University Nanoparticles for imaging and treating chlamydial infection
WO2009038656A1 (en) 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
CA2700257A1 (en) 2007-10-02 2009-04-09 Hartmut Land Methods and compositions related to synergistic responses to oncogenic mutations
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
CN102439453A (zh) 2009-05-20 2012-05-02 日内瓦大学 癌症起始细胞的线粒体活性抑制剂及其用途
HUE053793T2 (hu) 2009-12-04 2021-07-28 Oncoc4 Inc Hipoxia indukálta faktor gátlók alkalmazásai
WO2011140047A1 (en) 2010-05-04 2011-11-10 Trustees Of Dartmouth College Methods for identifying allosteric and other novel acyl-coenzyme a:cholesterol acyltransferase inhibitors
EP2606349A4 (en) * 2010-08-20 2014-04-30 Univ Jefferson AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
US20120141467A1 (en) 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US20130172430A1 (en) * 2010-12-10 2013-07-04 Michael P. Lisanti Prognosis and treatment of breast cancer
EA032840B8 (ru) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Пролекарства на основе конъюгатов противогрибковых агентов и их применение
US10441577B2 (en) 2011-07-08 2019-10-15 Helmholtz Zentrum Fuer Infektionsforschung Medicament for treatment of liver cancer
WO2013019975A1 (en) 2011-08-03 2013-02-07 University Of Iowa Research Foundation Compositions and methods of treating cancer
WO2013024467A2 (en) 2011-08-18 2013-02-21 Ecole Polytechnique Federale De Lausanne (Epfl) Mitochondrial ribosomal proteins as aging regulators
US9765063B2 (en) * 2011-09-09 2017-09-19 New York University Amido compounds as RORγt modulators and uses thereof
WO2013040206A1 (en) 2011-09-14 2013-03-21 Lewis Thomas J Novel formulations comprising macrolide and tetracycline and their uses
WO2013130968A1 (en) 2012-03-01 2013-09-06 University Of Cincinnati Ros-activated compounds as selective anti-cancer therapeutics
US9526795B2 (en) 2012-08-28 2016-12-27 Annam Biosciences, Llc N-BOC-dendrimers and their conjugates
US20150224169A1 (en) 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
WO2015002996A1 (en) 2013-07-01 2015-01-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
US20150231069A1 (en) 2014-02-20 2015-08-20 Pankaj Modi Oral formulations of chemotherapeutic agents
WO2015191668A1 (en) 2014-06-10 2015-12-17 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
US10413558B2 (en) 2014-10-17 2019-09-17 Targeted Therapies Research And Consulting Center Sprl Multi-ingredient pharmaceutical composition for use in cancer therapy
JP6439931B2 (ja) 2015-02-26 2018-12-19 大日本印刷株式会社 吸着搬送装置および吸着搬送方法
HK1259342A1 (zh) 2015-10-06 2019-11-29 Redhill Biopharma Ltd. 用於治疗癌症的联合疗法
JP2019528689A (ja) 2016-08-11 2019-10-17 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ 免疫調節化合物
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
US20200121739A1 (en) 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018202910A1 (en) 2017-05-05 2018-11-08 Fondazione Istituto Italiano Di Tecnologia Combination of antibiotic and bcl-2 inhibitor and uses thereof
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CN111315400A (zh) 2017-05-19 2020-06-19 卢内拉生物技术有限公司 Antimitoscin：用于根除癌症干细胞的线粒体生物发生的靶向抑制剂
WO2018218242A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Methods and compositions for combination therapy
CA3064452A1 (en) * 2017-06-26 2019-01-03 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells

Also Published As

Publication number Publication date
ZA202101954B (en) 2022-09-28
AU2020257159A1 (en) 2020-11-19
EP3644988A4 (en) 2021-03-03
SG11201913134UA (en) 2020-01-30
PE20200295A1 (es) 2020-02-05
CR20200033A (es) 2020-03-05
WO2019005698A1 (en) 2019-01-03
KR20240038805A (ko) 2024-03-25
US20200148688A1 (en) 2020-05-14
KR20200018814A (ko) 2020-02-20
AU2020257159B2 (en) 2022-07-14
DOP2022000142A (es) 2022-09-30
AU2018292283A1 (en) 2019-12-12
CO2019014259A2 (es) 2020-04-01
DOP2019000312A (es) 2020-03-15
CN110913854B (zh) 2023-04-28
US11667640B2 (en) 2023-06-06
PE20242070A1 (es) 2024-10-18
ZA201907831B (en) 2022-07-27
PH12019502892A1 (en) 2020-12-07
BR112019026097A2 (pt) 2020-07-07
IL292109B1 (en) 2023-10-01
JP7397672B2 (ja) 2023-12-13
MX2019014806A (es) 2020-02-10
KR102854338B1 (ko) 2025-09-03
JP2020525009A (ja) 2020-08-27
CN110913854A (zh) 2020-03-24
RU2020102908A3 (es) 2021-11-15
EP3644988A1 (en) 2020-05-06
ECSP20001729A (es) 2020-02-28
US20200207775A1 (en) 2020-07-02
IL292109B2 (en) 2024-02-01
EP3644988B1 (en) 2023-02-22
RU2020102908A (ru) 2021-07-27
KR102646172B1 (ko) 2024-03-13
AU2018292283B2 (en) 2020-07-23
CA3064452A1 (en) 2019-01-03
CU20190106A7 (es) 2020-11-30
IL292109A (en) 2022-06-01
IL270774A (en) 2020-01-30
US11667639B2 (en) 2023-06-06

Similar Documents

Publication Publication Date Title
CL2019003708A1 (es) Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas.
DOP2022000165A (es) MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS
UY37145A (es) Ligandos de direccionamiento
CO7461144A2 (es) Tratamiento de una formación subterránea con una composición que incluye un microorganismo o compuesto generado por este
MX2020004211A (es) Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial.
DOP2019000019A (es) Metodos para tratar el cancer de prostata
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
BR112016012870A8 (pt) composições e métodos para melhorar a produção de alface
BR112016003127A2 (pt) “composições e métodos para modular rna”
MX378277B (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
BR112017009330A2 (pt) planta transgênica que compreende um polinucleotídeo que codifica um domínio variável de anticorpo de cadeia pesada
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal
BR112018074304A2 (pt) composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos
BR112017018861A2 (pt) métodos para tratar câncer mantendo perda hemizigótica de tp53
BR112018071695A2 (pt) composições e métodos para a expressão gênica acentuada de pklr
BR112016025791A2 (pt) microrganismo modificado, método para produzir um composto orgânico e uso de um microrganismo modificado
AR098819A1 (es) Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry
BR112016018193A2 (pt) micro-organismo modificado, método de produção de composto orgânico e uso de micro-organismo modificado
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX2020003752A (es) Composición tópica y método para tratar y prevenir la dermatitis atópica e infecciones relacionadas con la biopelícula bacteriana.
AR101211A1 (es) Composición antimicrobiana sinérgica
BR112018009954A2 (pt) materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias